8.3.4 Hormone antagonists
Cyproterone
Cyproterone 50mg tablets
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Gender dysphoria or incongruence |
Goserelin
Zoladex 3.6mg implant SafeSystem pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Gender dysphoria or incongruence |
Zoladex LA 10.8mg implant SafeSystem pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Gender dysphoria or incongruence |
Lanreotide
Lanreotide 120mg/0.5ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Lanreotide 60mg/0.5ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Lanreotide 90mg/0.5ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Lanreotide
Lanreotide 120mg/0.5ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Lanreotide 60mg/0.5ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Lanreotide 90mg/0.5ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Leuprorelin
Prostap 3 DCS 11.25mg powder and solvent for prolonged-release suspension for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Gender dysphoria or incongruence |
Prostap SR DCS 3.75mg powder and solvent for prolonged-release suspension for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Gender dysphoria or incongruence |
Octreotide
Octreotide 100micrograms/1ml solution for injection ampoules
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Neuroendocrine tumours |
Octreotide 100micrograms/1ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Neuroendocrine tumours |
| Gastro-intestinal system | Short bowel syndrome |
Octreotide 100micrograms/1ml solution for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Neuroendocrine tumours |
Octreotide 1mg/5ml solution for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Gastro-intestinal system | Short bowel syndrome |
Octreotide 500micrograms/1ml solution for injection ampoules
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Neuroendocrine tumours |
Octreotide 500micrograms/1ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Neuroendocrine tumours |
Octreotide 500micrograms/1ml solution for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Neuroendocrine tumours |
Octreotide 50micrograms/1ml solution for injection ampoules
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Neuroendocrine tumours |
| Gastro-intestinal system | Short bowel syndrome |
Octreotide 50micrograms/1ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Neuroendocrine tumours |
| Gastro-intestinal system | Short bowel syndrome |
Olatuton 10mg powder and solvent for prolonged-release suspension for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Olatuton 20mg powder and solvent for prolonged-release suspension for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Olatuton 30mg powder and solvent for prolonged-release suspension for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Sandostatin LAR 10mg powder and solvent for suspension for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Sandostatin LAR 20mg powder and solvent for suspension for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Sandostatin LAR 30mg powder and solvent for suspension for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Triptorelin
Decapeptyl SR 11.25mg powder and solvent for suspension for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Gender dysphoria or incongruence |
Decapeptyl SR 22.5mg powder and solvent for suspension for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Gender dysphoria or incongruence |
Decapeptyl SR 3mg powder and solvent for suspension for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Gender dysphoria or incongruence |